A Multicenter, Three- arm, Double- blind, Double dummy, Parallel-group, placebo controlled Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily in comparison with conventional release formulation of Betahistine IR 24 mg, twice daily in treatment of adult patients with Menière's disease.
Latest Information Update: 04 Oct 2022
At a glance
- Drugs Betahistine (Primary)
- Indications Meniere's disease
- Focus Registrational; Therapeutic Use
- Acronyms BERTIGO
- Sponsors Intas Pharmaceuticals
Most Recent Events
- 04 Oct 2022 New trial record